Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

benzinga.com/markets/large-cap/25/06/45927887/novo-nordisk-moves-amycretin-into-phase-3-trials-for-weight-management-becomes-europes-largest-

Novo Nordisk A/S (NYSE:NVS) announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development in weight management.
Amycretin is developed for subcutaneous and oral administration.
The decision to advance subcutaneous and oral amycretin into phase 3 is…

This story appeared on benzinga.com, 2025-06-13 14:46:25.
The Entire Business World on a Single Page. Free to Use →